ArrowMark Colorado Holdings’s Tango Therapeutics TNGX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.1M	Hold	708,385	–	–	0.92%	17
2026 Q1	$14.8M	Hold	708,385	–	–	0.39%	75
2025 Q4	$6.28M	Hold	708,385	–	–	0.14%	176
2025 Q3	$5.95M	Hold	708,385	–	–	0.11%	187
2025 Q2	$3.63M	Hold	708,385	–	–	0.07%	205
2025 Q1	$970K	Hold	708,385	–	–	0.02%	251
2024 Q4	$2.19M	Hold	708,385	–	–	0.03%	228
2024 Q3	$5.45M	Hold	708,385	–	–	0.07%	183
2024 Q2	$6.08M	Hold	708,385	–	–	0.07%	185
2024 Q1	$5.62M	Hold	708,385	–	–	0.06%	200
2023 Q4	$7.01M	Buy	+708,385	New	+$6.15M	0.08%	177

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ArrowMark Colorado Holdings's TNGX Position: Q2 2026 in Review

ArrowMark Colorado Holdings held its Tango Therapeutics (TNGX) position steady in Q2 2026 at 708,385 shares worth $22.1M. The position accounts for 0.92% of the portfolio, ranked #17.

ArrowMark Colorado Holdings first reported a position in TNGX in Q4 2023 and has held it in 11 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

ArrowMark Colorado Holdings held 708,385 shares of Tango Therapeutics worth $22.1M as of Q2 2026.
ArrowMark Colorado Holdings left its Tango Therapeutics share count unchanged in Q2 2026.
Tango Therapeutics made up 0.92% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #17 holding.
ArrowMark Colorado Holdings first reported a position in Tango Therapeutics in Q4 2023 and has held it in 11 quarters since.
249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.